Paul-Ehrlich-Institut

Publikationen Dr. Michael Mühlebach

Autorinnen und Autoren des Paul-Ehrlich-Instituts sind durch Fettdruck kenntlich gemacht. Wenn Online-Abstracts oder Volltexte zu den Publikationen verfügbar sind, so sind diese verlinkt.

Hörner C, Schürmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon KH, Scholz T, Herrmann M, Schnierle B, Baric RS, Mühlebach MD (2020): A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine.
PNAS Nov 30 [Epub ahead of print].
Text

Mühlebach MD (2020): Measles virus in cancer therapy.
Curr Opin Virol Aug 27 [Epub ahead of print].
Online-Abstract

Turonova B, Sikora M, Schürmann C, Hagen WJH, Welsch S, Blanc FEC, Bülow von S, Gecht M, Bagola K, Hörner C, van Zandbergen G, Mosalaganti S, Schwarz A, Covino R, Mühlebach MD, Hummer G, Krijnse Locker J, Beck M (2020): In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges.
Science Aug 18 [Epub ahead of print].
Text

Hanauer JRH, Koch V, Lauer UM, Mühlebach MD (2019): High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency.
Mol Ther Oncolytics 15: 186-200.
Online-Abstract

Mühlebach MD, Cattaneo R: Development of Entry-Targeted Oncolytic Measles Viruses.
In: Engeland C (Hrsg.), Oncolytic Viruses. Methods in Molecular Biology (Vol. 2058). New York, NY: Humana, 2019. S. 51-75, ISBN 978-1-4939-9794-7

Nürnberger C, Bodmer BS, Fiedler AH, Gabriel G, Mühlebach MD (2019): A measles virus-based vaccine candidate mediates protection against Zika virus in an 1 allogenic mouse pregnancy model.
J Virol 93: e01485-18.
Online-Abstract

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G (2019): Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.
Mol Ther Oncolytics 12: 147-161.
Text

Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer S, Mühlebach MD (2018): Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
Virology 521: 99-107.
Online-Abstract

Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z (2018): Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro.
Mol Immunol 101: 19-28.
Online-Abstract

Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD (2017): Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
Sci Rep 7: 16892.
Text

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ (2017): Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.
Front Oncol 7: Article 127.
Text

Mühlebach MD, Hutzler S (2017): Development of Recombinant Measles Virus-Based Vaccines.
Methods Mole Biol 1581: 151-168.
Online-Abstract

Mühlebach MD (2017): Vaccine platform recombinant measles virus.
Virus Genes 53: 733-740.
Online-Abstract

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM (2017): Virotherapy Research in Germany: From Engineering to Translation.
Hum Gene Ther 28: 800-819.
Online-Abstract

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S (2016): Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.
Virology 489: 1-11.
Online-Abstract

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD (2016): Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.
Mol Ther Oncolytics 3: 16003.
Text

Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C (2016): APOBEC4 Enhances the Replication of HIV-1.
PLOS ONE 11: e0155422.
Text

Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Shams Eldin H, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD (2015): A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant MV vaccine platform.
J Virol 89: 11654-11667.
Online-Abstract

Scheuplein VA, Seifried J, Malczyk AH, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD (2015): High secretion of interferons by human plasmacytoid dendritic cells upon recognition of MERS-CoV.
J Virol 89: 3859-3869.
Online-Abstract

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD (2015): Lentiviral protein transfer vectors are an efficient vaccine-platform inducing strong antigen-specific cytotoxic T cell response.
J Virol 89: 9044-9060.
Online-Abstract

Weiss K, Gerstenberger J, Salzig D, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2015): Oncolytic measles viruses produced at different scales under serum-free conditions.
Eng Life Sci 15: 425-436.
Online-Abstract

Mühlebach MD, Hutzler S: Oncolytic viruses.
Britten CM, Kreiter S, Diken M, Rammensee HG (Hrsg.), Cancer Immunotherapy Meets Oncology. Cham: Springer International Publishing, 2014 ISBN 9783319051031

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Völker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 1-10.
Online-Abstract

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Muehlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 865-874.
Online-Abstract

Friedrich K, Hanauer JRH, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD (2013): DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.
Mol Ther 21: 849-859.
Online-Abstract

Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ (2013): Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.
Hum Gene Ther Clin Dev 24: 11-22.
Online-Abstract

Weiss K, Salzig D, Röder Y, Gerstenberger J, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2013): Influence of Process Conditions on Measles Virus Stability.
Am J Biochem Biotechnol 9: 243-254.
Online-Abstract

Weiss K, Salzig D, Mühlebach MD, Cichutek K, Pförtner R, Czermak P (2012): Key Parameters of Measles Virus Production for Oncolytic Virotherapy.
Am J Biochem Biotechnol 8: 81-98.
Online-Abstract

Mühlebach MD, Buchholz CJ, Götz KB (2011): Das Masernvirus im Fokus - von wirksamen und sicheren Impfstoffen über Krebstherapie bis hin zum Gentransfer.
Bulletin zur Arzneimittelsicherheit 2: 20-23.
Text

Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VHJ, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray Jr PB, Cichutek K, von Messling V, Lopez M, Cattaneo R (2011): Adherens junction protein nectin-4 (PVRL4) is the epithelial receptor for measles virus.
Nature 480: 530-533.
Text

Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ (2011): DARPins: an efficient targeting domain for lentiviral vectors.
Mol Ther 19: 686-693.
Online-Abstract

Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuss H, Hamdorf M, Schweitzer M, Cichutek K, Flory E (2011): Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease.
Retrovirology 8: 14.
Online-Abstract

Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M (2010): Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.
J Gene Med 12: 446-452.
Online-Abstract

Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KMO, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ (2010): Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Cancer Res 70: 7620-7629.
Online-Abstract

Mühlebach MD, Schüle S, Gerlach N, Schweizer M, Buchholz CJ, Hohenadl C, Cichutek K: Gammaretroviral and Lentiviral Vectors for Gene Delivery.
In: Kurth R, Bannert N (Hrsg.), Retroviruses: Molecular Biology, Genomics and Pathogenesis. Norfolk: Caister Academic Press, 2010. 347-370 ISBN 9781904455554

Buchholz CJ, Mühlebach MD, Cichutek K (2009): Lentiviral vectors with measles virus glycoproteins – dream team for gene transfer?.
Trends Biotechnol 27: 259-265.
Online-Abstract

Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ (2009): Pseudotyping lentiviral vectors with the wildtype measles virus glycoproteins improves titer and selectivity.
Gene Ther 16: 700-705.
Online-Abstract

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ (2008): Targeted cell entry of lentiviral vectors.
Mol Ther 16: 1427-1436.
Online-Abstract

Mühlebach MD, Leonard VHJ, Cattaneo R (2008): The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion efficiency.
J Virol 82: 11437-45.
Online-Abstract

Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M (2007): Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.
Virology 364: 330-341.
Online-Abstract

Mühlebach MD, Wolfrum N, Schüle S, Tschulena U, Sanzenbacher R, Flory E, Cichutek K, Schweizer M (2005): Stable Transduction of Primary Human Monocytes by Simian Lentiviral Vector PBj.
Mol Ther 12: 1206-1216.

Steidl S, Schüle S, Mühlebach MD, Stitz J, Boller K, Cichutek K, Schweizer M (2004): Genetic engineering of onco/lentivirus hybrids results in formation of infectious particles but not of replication-competent viruses.
J Gen Virol 85: 665-678.
Online-Abstract

Mühlebach MD, Schmitt I, Steidl S, Stitz J, Schweizer M, Blankenstein T, Cichutek K, Uckert W (2003): Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.
J Mol Med 81: 801-810.
Online-Abstract

Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K (2001): A Novel Lentivirus vector derived from apathogenic simian immunodeficiency virus.
Virology 291: 191-197.
Online-Abstract